Cambridge, MA, Oct. 18, 2012 (GLOBE NEWSWIRE) -- LaVoie Strategic Communications Group, Inc. (LaVoie Group), the acknowledged leader in life science, medtech and pharmaceutical communications, today released a white paper on the nuances of building an effective communications strategy around drug development and commercialization of orphan drugs.
When approaching communications for orphan disease products and the organizations developing them, companies often neglect to craft their strategies to address the specific needs of the rare disease environment. For public companies, this task can be further complicated by the need to balance investor communications, while also reaching patients, providers and payers.
The white paper outlines the unique qualities of the orphan disease environment and how best to plan communications programs and implement them successfully through the various phases of development.
"LaVoie Group has built a great depth of experience in the life science communications, and in particular orphan diseases, particularly relating to the unique challenges presented when communicating to the various stakeholders," said Donna L. LaVoie, president and chief executive officer of LaVoie Group. "Today, orphan diseases are top of mind for our industry including biotech, pharmaceutical companies and patient organizations, and our objective in developing this white paper is to share some of our knowledge and create a dialogue."
LaVoie Group and its executives have established expertise in orphan drug communications over a number of years, providing strategic communications counsel, including corporate communications, public relations and investor relations for numerous companies, including Aegerion Pharmaceuticals, Genzyme Corporation (now Sanofi), Pfizer, Inc. and Vertex Pharmaceuticals.
To download a free copy of the white paper, please visit: http://www.lavoiegroup.com/agency-news/blog.html
LaVoie Group partners with its clients achieve their business goals by providing strategic consulting and integrated communications programs that properly position, engage target customers and stakeholders to create brand value. LaVoie Group is part of the IPREX network of global agencies.
Our clients are industry leaders in healthcare and government markets, including, Aegerion Pharmaceuticals, AliveCor, Vertex Pharmaceuticals, BIO, Radius Health, Novadaq Technologies, Rockwell Medical, the Commonwealth of Massachusetts, Hydra Biosciences and Xcovery Group of companies. LaVoie Group is part of INC. 500/500 private company list and is ranked by O'Dwyer's PR Report as one of the leading independent healthcare PR firms in the U.S. and has been honored for the past four years by the League of American Communications Professionals (LACP) for best agency awards, including the 2011 "Best Small Agency". The agency has been honored by sixteen awards in the last three years.